Our Science
Disease Area
- Multiple
Modality
- Multiple
Disease Area
- Multiple
Modality
- Multiple
By: Dr. Alison Betts, Vice President of Scientific Collaborations and Fellow of Modeling & Simulation of Applied BioMath
Disease Area
- Oncology
- Immuno-oncology
Modality
- Multiple

Collaboration with Pfizer - Published in CPT: Pharmacometrics & Systems Pharmacology
Disease Area
- Immuno-oncology
Modality
- mAb
Disease Area
- Other
Modality
- Other

Collaboration with Biogen - Published in CPT: Pharmacometrics Systems Pharmacology
Disease Area
- Neuroscience
Modality
- mAb
Published in the Journal of Pharmacokinetics and Pharmacodynamics
Disease Area
- Other
Modality
- Other

Collaboration with Genmab - Presented at SITC 2021
Disease Area
- Immuno-oncology
Modality
- Bispecific

Collaboration with Antengene - Presented at SITC 2021
Disease Area
- Oncology
Modality
- Bispecific

Collaboration with OncoMyx Therapeutics - Presented at the American Association for Cancer Research, Annual Meeting 2021
Disease Area
- Immuno-oncology
Modality
- Small Molecule
Disease Area
- Rare Disease
Modality
- Other
Published in Pharma Tech Outlook Magazine
Disease Area
- Multiple
Modality
- Bispecific
- mAb